Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Oswaldo L. Castro, MDDr. Oswaldo Castro is Professor Emeritus...
-
Sickle Cell Anemia Foundation of OregonThe Sickle Cell Anemia Foundation of Ore...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
Roald Dahl’s Marvellous Children’s Charity “Everyone’s Business” campaignhttps://www.youtube.com/watch?v=VqdP3Sxa...
-
Nadine Matthie, PhD, RNNadine Matthie is an assistant professor...
-
Individualized pain plans significantly reduce hospitalization in pediatric sickle cell patients with vaso-occlusive...Background: Vaso-occlusive crisis (VOC)...
-
How organ and tissue transplants can affect buying life insuranceEach day in the United States, about 80 ...
